Geisinger, Indivumed Partner on Personalized Cancer Medicine | GenomeWeb

NEW YORK (GenomeWeb News) – Geisinger Health System today announced a partnership with German firm Indivumed aimed at providing Geisinger's patients access to advanced cancer treatments and clinical trials.

Under the terms of the deal, Indivumed will have access to tissue samples from consenting Geisinger patients for molecular and biochemical profiling. Patients already undergoing a surgical tumor resection will have a portion of the tissue, blood, or urine banked by Geisinger through MyCode, a repository that currently contains 43,000 patient samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.